A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer.
Mahdi ShadnoushMehrnaz MomenanVeronique SeidelSascha TierlingNayeralsadat FatemiEhsan Nazemalhosseini-MojaradMohammad Tayefeh NoroozMakan CheraghpourPublished in: Pharmacological reports : PR (2024)
Colorectal cancer (CRC) is one of the most common cancers and a major cause of cancer-related mortality worldwide. The efficacy of chemotherapy agents in CRC treatment is often limited due to toxic side effects, heterogeneity of cancer cells, and the possibility of chemoresistance which promotes cancer cell survival through several mechanisms. Combining chemotherapy agents with natural compounds like curcumin, a polyphenol compound from the Curcuma longa plant, has been reported to overcome chemoresistance and increase the sensitivity of cancer cells to chemotherapeutics. Curcumin, alone or in combination with chemotherapy agents, has been demonstrated to prevent chemoresistance by modulating various signaling pathways, reducing the expression of drug resistance-related genes. The purpose of this article is to provide a comprehensive update on studies that have investigated the ability of curcumin to enhance the efficacy of chemotherapy agents used in CRC. It is hoped that it can serve as a template for future research on the efficacy of curcumin, or other natural compounds, combined with chemotherapy agents to maximize the effectiveness of therapy and reduce the side effects that occur in CRC or other cancers.
Keyphrases
- locally advanced
- signaling pathway
- randomized controlled trial
- poor prognosis
- systematic review
- risk factors
- chemotherapy induced
- type diabetes
- cell proliferation
- single cell
- papillary thyroid
- long non coding rna
- climate change
- mesenchymal stem cells
- bone marrow
- mass spectrometry
- binding protein
- replacement therapy
- atomic force microscopy
- single molecule
- smoking cessation
- childhood cancer